The Clinical Research Core will provide centralized, quality controlled services for specimen processing, regulatory protocol management, development of Standard Operating Procedures, and limited specialized assay testing to support the research of Projects 1,2,3 and 4. The core will be responsible for the identification, recruitment, and phlebotomy of individuals to support U19 research objectives as well as the regulatory oversight of IRB protocols related to U19 research. Through the efforts of research associates and technicians, the core will be responsible for the processing and storage of the blood and serum samples obtained. The core will be responsible for a Quality Control Materials program to provide services related to Quality assurance of reagents and assays used in U19 research. This would include the establishment and optimization of standardized protocols, the development of a centralized comprehensive repository of positive control cell lines, the establishment of subject registry related to immunological characteristics of interest and the performance of established T cell assays to determine antigen specificity of PBMC samples and reagents. In addition, the clinical research core will provide a limited number of HLA typings for each of the proposed U19 projects.
The scope of the research encompassed by the four U19 investigator-initiated projects and the Technology Development Project would benefit not only from the shared cost of the resources of the proposed clinical core but also from the structure to standardize and disseminate new technologies that are developed within the individual projects.
|Townsley, E; O'Connor, G; Cosgrove, C et al. (2016) Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol 183:419-30|
|Woda, Marcia; Friberg, Heather; Currier, Jeffrey R et al. (2016) Dynamics of Dengue Virus (DENV)-Specific B Cells in the Response to DENV Serotype 1 Infections, Using Flow Cytometry With Labeled Virions. J Infect Dis 214:1001-9|
|Ramirez, Alejandro; Co, Mary; Mathew, Anuja (2016) CpG Improves Influenza Vaccine Efficacy in Young Adult but Not Aged Mice. PLoS One 11:e0150425|
|Becerra-Artiles, Aniuska; Dominguez-Amorocho, Omar; Stern, Lawrence J et al. (2015) A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B. PLoS One 10:e0142871|
|Woda, Marcia; Mathew, Anuja (2015) Fluorescently labeled dengue viruses as probes to identify antigen-specific memory B cells by multiparametric flow cytometry. J Immunol Methods 416:167-77|
|Jaiswal, Smita; Smith, Kenneth; Ramirez, Alejandro et al. (2015) Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med (Maywood) 240:67-78|
|Tervo, Laura; MÃ¤kelÃ¤, Satu; SyrjÃ¤nen, Jaana et al. (2015) Smoking is associated with aggravated kidney injury in Puumala hantavirus-induced haemorrhagic fever with renal syndrome. Nephrol Dial Transplant 30:1693-8|
|Thompson, Mikayla R; Sharma, Shruti; Atianand, Maninjay et al. (2014) Interferon Î³-inducible protein (IFI) 16 transcriptionally regulates type i interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA viruses. J Biol Chem 289:23568-81|
|Mathew, Anuja; Townsley, Elizabeth; Ennis, Francis A (2014) Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol 9:411-25|
|Yin, Liusong; Stern, Lawrence J (2014) A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination. J Immunol Methods 406:21-33|
Showing the most recent 10 out of 105 publications